Status:

COMPLETED

A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

Lead Sponsor:

MEDA Pharma GmbH & Co. KG

Conditions:

Actinic Keratoses

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of the study is to obtain recurrence rates and long-term safety data for patients who had been treating actinic keratoses on the face and scalp with 5 % Imiquimod Cream in a previous study...

Eligibility Criteria

Inclusion

  • 100% clearance of Actinic Keratosis (AK) lesions in the 1487 IMIQ study

Exclusion

  • used any treatments in the previous treatment area within 24 hours prior to the follow-up visit

Key Trial Info

Start Date :

April 1 2005

Trial Type :

OBSERVATIONAL

End Date :

November 1 2005

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT00189254

Start Date

April 1 2005

End Date

November 1 2005

Last Update

February 7 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.